Physician profile
Brandon G Busbee
NPI 1609952654
$566,104.03
in general payments reported to CMS, 2019-2025
22 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,588 · 2021: $8,302 · 2022: $136K · 2023: $229K · 2024: $155K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $339K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $8,935 · Food and Beverage: $3,244 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $338,580.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,228.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,590.00 |
| Travel and Lodging | $8,934.50 |
| Food and Beverage | $3,244.04 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $440,198.60 | 2022-2024 | Akten |
| Apellis Pharmaceuticals, INC. | $60,181.36 | 2023-2025 | Syfovre |
| US Retina LLC | $33,528.30 | 2019-2022 | |
| Genentech USA, INC. | $18,076.92 | 2019-2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $10,834.33 | 2019-2021 | |
| Allergan, INC. | $1,714.41 | 2019-2020 | |
| Astellas Pharma US INC | $492.67 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $214.32 | 2019-2025 | Eylea Hd |
| Dutch Ophthalmic, USA | $140.42 | 2024 | Tissueblue, Eva, Combined Machine |
| Neurotech Pharmaceuticals, INC. | $125.22 | 2025 | |
| Abbvie INC. | $116.97 | 2022-2025 | Ozurdex |
| Biogen, INC. | $94.55 | 2022-2024 | Byooviz |
| Bausch & Lomb Americas INC. | $82.83 | 2024 | Stellaris |
| Iridex Corporation | $64.58 | 2021 | |
| Coherus Oncology, INC. | $63.23 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.01 | 2019-2020 | |
| Eyepoint US, INC. | $46.05 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $22.72 | 2019 | |
| Alcon Vision LLC | $21.65 | 2022 | |
| Alimera Sciences, INC. | $21.61 | 2021 | |
| Amgen INC. | $15.28 | 2025 | Pavblu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$114,285.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Busbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.